Munich, 12. December 2019 (fcf) – Enno Spillner is joining the Life Sciences Advisory Board of FCF Fox Corporate Finance GmbH.
The Munich-based finance specialist has gained a further renowned expert for its Life Sciences Advisory Board.
FCF Fox Corporate Finance GmbH (“FCF”) has gained a further renowned expert for its Life Sciences Advisory Board. As of now, Enno Spillner will support and advise the finance specialist in all matters of the Life Sciences business sector.
Since 2016, Enno Spillner has been the Chief Financial Officer (CFO) of Evotec, a MDAX- and TecDAX-listed biotech company with more than 2,900 employees and a market capitalization of approximately Euro 3 billion. As recently as June 2019, he issued the first bond in the company’s history of Evotec, which achieved a volume of approximately Euro 250 million, a capital cost ratio very favorable to the biotech sector. In addition to such financial transactions, Enno Spillner has been involved in the design and completion of many M&A and equity transactions in recent years.
Dr. Mathias Schott, Director Life Sciences of FCF, is very happy about this new advisory board member: “Enno Spillner has strongly demonstrated his expertise in particular by his success story at Evotec, and we are therefore all the more pleased to welcome this experienced member onto our Life Sciences Advisory Board.”
Since 2018, the Life Sciences Advisory Board has been a central element of the corporate strategy of FCF in the Life Science business sector, focusing on highly innovative companies of the biotechnology and medical technology sector. Arno Fuchs, General Manager of FCF, explains: “Our aim for the Life Sciences business sector continues to acquire the best expertise for the advisory board and to closely tie this board into the operating business, so as to provide our clients with the best possible solutions in financing matters. Hence, the Life Science Advisory Board has always made a major contribution to the success of FCF.”